[Federal Register Volume 82, Number 35 (Thursday, February 23, 2017)]
[Notices]
[Page 11475]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03452]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

CD300b Expression Exacerbates Endotoxemia and Septic Peritonitis

    Description of Technology: The innate immune system is the first 
line of host defense against invading pathogens. Lipopolysaccharides 
(LPS), present in gram-negative bacteria membranes, cause strong immune 
responses following detection by the Toll-like receptor 4 (TLR4) on 
immune cells. This detection results in the release of pro-inflammatory 
cytokines, such as tumor necrosis factor alpha, interleukin-6, and 
interferon gamma, to assist with clearance of the infectious insult. In 
parallel, interleukin-10 (IL-10), an anti-inflammatory cytokine, is 
induced to limit the immune response. This is because unchecked immune 
activation leads to a more severe immunopathology, such as septic shock 
and subsequently death. Current therapies to treat sepsis are 
ineffective, and clinical trials based on neutralization of specific 
inflammatory cytokines have failed.
    The inventors, listed below, have discovered that CD300b is a LPS 
binding receptor. This interaction results in a reduced IL-10 
production, leading to an amplification of lethal inflammation. In 
vitro, anti-CD300b antibodies block LPS binding to CD300b, stopping 
association with TLR4 and CD14 and increases IL-10 levels. In vivo, 
administration of anti-CD300b antibodies protects animals from septic 
shock, due to a reduce level of pro-inflammatory cytokines but 
subsequent increase in the anti-inflammatory cytokine, IL-10.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications: As a means of treating 
endotoxemia and septic peritonitis.
    Competitive Advantages: No current therapeutics are available to 
treat septic shock.
    Development Stage: Pre-clinical.

    Inventors:

John E. Coligan, NIAID, NIH
Oliver H. Voss, NIAID, NIH
Konrad Krzewski, NIAID, NIH

    Publications: Voss, Oliver H., et al. ``Lipopolysaccharide-induced 
CD300b receptor binding to toll-like receptor 4 alters signaling to 
drive cytokine responses that enhance septic shock.'' Immunity 44.6 
(2016): 1365-1378.
    Intellectual Property: HHS Reference No. E-112-2016/0--U.S. Patent 
Application No. 62/308,144 filed 03/14/2016.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
co-develop CD300b antagonists. For collaboration opportunities, please 
contact Chris Kornak, 240-627-3705, [email protected].

    Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-03452 Filed 2-22-17; 8:45 am]
 BILLING CODE 4140-01-P